EBV miRNAs BART11 and BART17-3p promote immune escape through the enhancer-mediated transcription of PD-L1.

EBV miRNAs BART11 and BART17-3p promote immune escape through the enhancer-mediated transcription of PD-L1.
复制标题

EBV miRNA BART11 和 BART17-3p 通过增强子介导的 PD-L1 转录促进免疫逃逸

DOI:
10.1038/s41467-022-28479-2
复制
发表时间:
2022-02-14
影响因子:
16.6
通讯作者:
Zeng Z
Zeng Z
中科院分区:
综合性期刊1区
文献类型:
--
作者:
Wang J;Ge J;Wang Y;Xiong F;Guo J;Jiang X;Zhang L;Deng X;Gong Z;Zhang S;Yan Q;He Y;Li X;Shi L;Guo C;Wang F;Li Z;Zhou M;Xiang B;Li Y;Xiong W;Zeng Z

文献摘要

参考文献

被引文献

相似文献

据报道,EB病毒(EBV)是第一个发现的人类肿瘤病毒,与鼻咽癌(NPC)、胃癌(GC)和多种淋巴瘤的发生和发展密切相关。 PD-L1 表达在 EBV 阳性的 NPC 和 GC 组织中升高;然而,EBV 依赖性促进 PD-L1 表达诱导免疫逃逸的具体机制需要澄清。 EBV 编码 44 种成熟 miRNA。在本研究中,我们发现 EBV-miR-BART11 和 EBV-miR-BART17-3p 上调 EBV 相关 NPC 和 GC 中 PD-L1 的表达。此外,EBV-miR-BART11 靶向 FOXP1,EBV-miR-BART17-3p 靶向 PBRM1,FOXP1 和 PBRM1 结合 PD-L1 的增强子区域以抑制其表达。因此,EBV-miR-BART11和EBV-miR-BART17-3p分别抑制FOXP1和PBRM1,并增强PD-L1(CD274,http://www.ncbi.nlm.nih.gov/gene/29126)的转录,从而促进肿瘤免疫逃逸,这为EBV相关肿瘤免疫治疗的潜在靶点提供了见解。
Epstein-Barr virus (EBV) is reportedly the first identified human tumor virus, and is closely related to the occurrence and development of nasopharyngeal carcinoma (NPC), gastric carcinoma (GC), and several lymphomas. PD-L1 expression is elevated in EBV-positive NPC and GC tissues; however, the specific mechanisms underlying the EBV-dependent promotion of PD-L1 expression to induce immune escape warrant clarification. EBV encodes 44 mature miRNAs. In this study, we find that EBV-miR-BART11 and EBV-miR-BART17-3p upregulate the expression of PD-L1 in EBV-associated NPC and GC. Furthermore, EBV-miR-BART11 targets FOXP1, EBV-miR-BART17-3p targets PBRM1, and FOXP1 and PBRM1 bind to the enhancer region of PD-L1 to inhibit its expression. Therefore, EBV-miR-BART11 and EBV-miR-BART17-3p inhibit FOXP1 and PBRM1, respectively, and enhance the transcription of PD-L1 (CD274, http://www.ncbi.nlm.nih.gov/gene/29126), resulting in the promotion of tumor immune escape, which provides insights into potential targets for EBV-related tumor immunotherapy.
PD-L1 通过 NF-kappa B 途径被 EBV 驱动的 LMP1 上调,并与自然杀伤/T 细胞淋巴瘤的不良预后相关
DOI: 10.1186/s13045-016-0341-7
发表时间: 2016-10-13
影响因子: 28.5
作者:
Bi XW;Wang H;Zhang WW;Wang JH;Liu WJ;Xia ZJ;Huang HQ;Jiang WQ;Zhang YJ;Wang L
通讯作者: Wang L
Epstein-Barr 病毒 miR-BART6-3p 抑制 RIG-I 通路
DOI: 10.1159/000479749
发表时间: 2017-01-01
影响因子: 5.3
作者:
Lu, Yuanjun;Qin, Zailong;Ma, Jian
通讯作者: Ma, Jian
DOI: 10.1371/journal.ppat.1003974
发表时间: 2014-02
期刊: PLoS pathogens
影响因子: 6.7
作者:
Hsu CY;Yi YH;Chang KP;Chang YS;Chen SJ;Chen HC
通讯作者: Chen HC
DOI: 10.1371/journal.pone.0125013
发表时间: 2015
期刊: PloS one
影响因子: 3.7
作者:
Li H;Yu B;Li J;Su L;Yan M;Zhang J;Li C;Zhu Z;Liu B
通讯作者: Liu B
DOI: 10.1016/j.celrep.2017.04.031
发表时间: 2017-05-09
期刊: Cell reports
影响因子: 8.8
作者:
Garcia-Diaz A;Shin DS;Moreno BH;Saco J;Escuin-Ordinas H;Rodriguez GA;Zaretsky JM;Sun L;Hugo W;Wang X;Parisi G;Saus CP;Torrejon DY;Graeber TG;Comin-Anduix B;Hu-Lieskovan S;Damoiseaux R;Lo RS;Ribas A
通讯作者: Ribas A